GLORIA

GEOMAR Library Ocean Research Information Access

X

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • American Association for Cancer Research (AACR)  (2)
Material
Publisher
  • American Association for Cancer Research (AACR)  (2)
Person/Organisation
Language
Years
Subjects(RVK)
  • 1
    Online Resource
    Online Resource
    Abstract 4650: From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia.
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4650-4650
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 4650-4650
    Abstract: Background: We have provided initial evidence1 on the clinical usefulness of the cancer cachexia stages (CCS) proposed by Fearon et al2. However it is still unclear3 if particular molecular phenotypes are also associated with these stages, as well with relevant clinical outcomes. Methods: A candidate list of cytokines (Activin A, Eotaxin, FGF, G-CSF, GDF15, GM-CSF, IFN-g, IL-10, IL-12_p70, IL-13, IL-15, IL-17, IL-1b, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IP-10, MCP-1_MCAF, MIP-1a, MIP-1b, PDGF-bb, RANTES, TNF-a, VEGF) was measured in 210 blood samples from patients with advanced lung and gastrointestinal cancers, via Luminex and ELISA methods. Non-parametric t-test, Kaplan-Meier and Kruskal-Wallis analyses were used to test the association between cytokines levels with CCS, Patient-Generated Subjective Global Assessment scores (PG-SGA) and survival. Results: Using non-cachectic patients as controls, Activin A and GDF15 were significantly up-regulated in pre-cachectic (p & lt;0.01), cachectic (p & lt;0.05) and refractory cachectic (p & lt;0.001) patients. IL-6, IL-8 and VEGFa were significantly up-regulated only in refractory cachectic (p & lt;0.001) patients. Activin A (p & lt;0.001), GDF15 (p & lt;0.001) and IL-8 (P & lt;0.001) plasma levels correlated with PG-SGA. Quartiles of GDF15 plasma levels identified better survival curves as compared to Activin A, IL-6 and IL-8 quartiles. Conclusions: Activin A and GDF15 appear to be useful aids for the diagnosis of all cachexia stages in advanced cancer. Because of their correlation with nutritional and survival outcomes, these cytokines may also represent useful targets in the development of new compounds for the treatment of cancer cachexia. 1. Vigano A, Del Fabbro E, Bruera E, Borod M. The cachexia clinic: from staging to managing nutritional and functional problems in advancer cancer patients. Critical Reviews in Oncogenesis, 2012 17(3), 293-304 2. Fearon K,Strasser F,Anker SD,Bosaeus I,Bruera E,Fainsinger RL,Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, Radbruch L, Ravasco P, Walsh D, Wilcock A, Kaasa S, Baracos VE. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12:489-495. 3. Scheede-Bergdahl, C., Watt, H.L., Trutschnigg, B., Kilgour, R.D., Haggarty, A., Lucar, E., Vigano, A. 2011. Is IL-6 the best pro-inflammatory biomarker of clinical outcomes of cancer cachexia? Clinical Nutrition 31: 85-8. Citation Format: Antonio Vigano, Lorena Lerner, Nianjun Tao, Brian Krieger, Bin Feng, Richard Nicoletti, Qing Liu, Ailin Bai, Zhigang Weng, Thierry Alcindor, Domenico Fuoco, Jeno Gyuris, Maria Isabel Chiu. From bench to bedside: are cytokines still relevant biomarkers for staging cancer cachexia. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4650. doi:10.1158/1538-7445.AM2013-4650
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2013-4650
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
  • 2
    Online Resource
    Online Resource
    Abstract 3504: Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients.
    American Association for Cancer Research (AACR) ; 2013
    In:  Cancer Research Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3504-3504
    Details
    In: Cancer Research, American Association for Cancer Research (AACR), Vol. 73, No. 8_Supplement ( 2013-04-15), p. 3504-3504
    Abstract: Background: Cachexia is associated with increased inflammatory markers and decreased survival in cancer. Also, elevated GDF-15 has been associated with poor prognosis in several cancer types but its role in cachexia is not well-understood. Methods: We measured body weight change, appetite, plasma GDF-15, and other inflammatory markers in 62 males with cancer-cachexia (CC), 72 non-cachectic cancer subjects (CNC) and 64 non-cancer controls (Co) matched by age, gender and pre-illness body weight. In a subset of patients we also measured grip strength (HGS), appendicular lean body mass (aLBM), ECOG and KPS. Results: GDF-15, IL-6 and IL-8 were increased in CC vs. other groups. Activin and G-CSF were significantly upregulated in CC vs. Co. A subset analyses showed that GDF-15, Activin A and IL-8 were increased in CC vs. CNC in lung cancer patients and that GDF-15, IL-6 and IL-8 were increased in CC patients treated with platinum-based chemotherapy. GDF15, IL-6 and IL-8 levels significantly correlated with 6-month weight loss and with IL-6, IL-1ra, IL-2, IL-4, IL-9, IL-10, IFN, MCP-10, MIP-1a, MIP-1b, TNF-a, VGEF and activin in cancer patients. Analysis in a subset of patients showed that CC had lower grip strength, aLBM, and fat mass; and that ECOG and KPS were lower in CC and CNC compared to controls. GDF-15 and IL-8 correlated negatively with aLBM, HGS and fat mass. Activin correlated negatively with aLBM. Survival analysis showed that GDF-15 and IL-8 predicted survival adjusting for stage and weight change (Cox regression p & lt;0.01, HR 3). Conclusion: GDF-15 and other inflammatory markers are associated with weight loss, decreased muscle mass and strength and poor survival in cancer patients. GDF-15 may serve as a prognostic indicator in cancer patients and be a novel therapeutic target for cancer cachexia. Citation Format: Lerner Lorena, Teresa Hayes, Nianjun Tao, Brian Krieger, Bin Feng, Richard Nicoletti, Ailin Bai, Zhigang Weng, Qing Liu, Maria Isabel Chiu, Jeno Gyuris, Jose M. Garcia. Plasma growth differentiating factor-15 (GDF-15) and other inflammatory markers are associated with weight loss and poor prognosis in cancer patients. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3504. doi:10.1158/1538-7445.AM2013-3504
    Type of Medium: Online Resource
    ISSN: 0008-5472 , 1538-7445
    URL: Article
    DOI: 10.1158/1538-7445.AM2013-3504
    RVK:
    XA 36000
    RVK:
    XA 10000
    Language: English
    Publisher: American Association for Cancer Research (AACR)
    Publication Date: 2013
    detail.hit.zdb_id: 2036785-5
    detail.hit.zdb_id: 1432-1
    detail.hit.zdb_id: 410466-3
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
    Online Resource
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...